Introduction: Breast cancer is the most frequent malignancy in women with more than one in ten new cancer diagnoses each year. Synthetic products are a key source for the identification of new anticancer medicines and drug leads.
Objectives: Imidazopyrazine is a highly favored skeleton for the design of new anticancer drugs. designed derivatives were screened using computer aided drug design techniques and validated using MTT assay.
Methods: A template-based methodology was used in the current work to create novel Imidazopyrazine derivatives, targeting the NPY1R protein. Molecular docking, Diffusion docking, MD simulation, MM-GBSA and meta-dynamics techniques were followed. MTT assay was performed to validate the activity of principal compound.
Results: A docking score of -6.660 and MMGBSA value of -108.008 (+/-) 9.14 kcal/mol was obtained from the investigations conducted. In addition, molecular dynamics simulation was carried out for 500 ns, yielding a stable RMSD and value of 5.6 Å, thus providing insights on the stability of the protein conformation on interaction with the principal compound. Furthermore, the validation studies conducted via MTT assay showed an IC value of 73.45 (+/-) 0.45 μg /mL.
Conclusion: The research has produced encouraging findings and can be applied as a model for precise enumerations in the future. It also encourages the study of novel synthetic compounds with potential anti-cancer properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871520623666230505100031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, Synthesis, Anticancer Evaluation and In Silico Studies of Imidazole Pyrazine Compounds.
Chem Biodivers
November 2024
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.
The present study focused on design and synthesis novel imidazolopyrazine derivatives, investigate the effect of them on the proliferation and migration of several human cancer cell lines by CCK-8 method, and interactions with the JAKs by reverse molecular docking. It was found that most of the synthesized imidazolopyrazin derivatives exhibited excellent inhibitory effects towards three tested tutor cells in vitro. Among them, three compounds have IC values much lower than Fluorouracil while show low toxicity to normal cells L-02.
View Article and Find Full Text PDFDirect-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors.
Bioorg Med Chem Lett
March 2024
Department of Drug Discovery, IRBM S.p.A., Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.
Tyrosine phosphatase SHP2 is a proto-oncogenic protein involved in cell growth and differentiation via diverse intracellular signaling pathways. With the scope of identifying new SHP2 allosteric inhibitors, we report here the development and optimization of a high-throughput "Direct-to-Biology" (D2B) workflow including the synthesis and the biological evaluation of the reaction crude, thus eliminating the need for purification. During this labor-saving procedure, the structural diversity was introduced through a SNAr reaction.
View Article and Find Full Text PDFFused Imidazopyrazine-Based Tubulin Polymerization Inhibitors Inhibit Neuroblastoma Cell Function.
ACS Med Chem Lett
September 2023
Department of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
Targeting the colchicine binding site on tubulin is a promising approach for cancer treatment to overcome the limitations of current tubulin polymerization inhibitors. New classes of colchicine binding site inhibitors (CBSIs) are continually being uncovered; however, balancing metabolic stability and cellular potency remains an issue that needs to be resolved. Therefore, we designed and synthesized a series of novel fused imidazopyridine and -pyrazine CBSIs and evaluated their cellular activity, metabolic stability, and tubulin-binding properties.
View Article and Find Full Text PDFDesign of Novel Imidazopyrazine Derivative against Breast Cancer Targeted NPY1R Antagonist.
Anticancer Agents Med Chem
September 2023
Bangalore Bioinnovation Centre, Helix Biotech Park, Electronics City Phase 1, Bengaluru, 560100, Karnataka, India.
Introduction: Breast cancer is the most frequent malignancy in women with more than one in ten new cancer diagnoses each year. Synthetic products are a key source for the identification of new anticancer medicines and drug leads.
Objectives: Imidazopyrazine is a highly favored skeleton for the design of new anticancer drugs.
Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors.
ACS Med Chem Lett
February 2023
Department of Drug Discovery IRBM S.p.A., Pomezia, Rome 00071, Italy.
Protein tyrosine phosphatase SHP2 is an oncogenic protein that can regulate different cytokine receptor and receptor tyrosine kinase signaling pathways. We report here the identification of a novel series of SHP2 allosteric inhibitors having an imidazopyrazine 6,5-fused heterocyclic system as the central scaffold that displays good potency in enzymatic and cellular assays. SAR studies led to the identification of compound , a highly potent SHP2 allosteric inhibitor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!